RACURA ONCOLOGY ORDINARY (RAC) Short Interest

Name: RACURA ONCOLOGY ORDINARY (RAC) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

RACURA ONCOLOGY ORDINARY (ASX:RAC) had 0.02% of shares reported as short positions as of 4 June 2026, representing 34,947 shares. RACURA ONCOLOGY ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).

Short interest: 0.02%
Reported positions: 34,947
Industry: Pharmaceuticals, Biotechnology & Life Sciences
As of: 4 June 2026

Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.

RAC

Racura Oncology

Pharmaceuticals, Biotechnology & Life Sciences

Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.

Pharmaceuticals

Biotechnology

Oncology

Clinical Trials

Shorted

short percentage0.02%

reported shorts34.9K

shares on issue192.309M